Nitro-Dur Shortage: What Providers and Prescribers Need to Know in 2026

For cardiology practices and primary care providers managing patients on long-acting nitrates, the nitroglycerin supply landscape in 2026 warrants proactive attention. While transdermal nitroglycerin patches (Nitro-Dur, Minitran, and generics) have been less affected than sublingual tablets and injectable forms, localized stocking issues continue to impact patients. This clinical overview outlines what prescribers should know and how to prepare patients.

Current Supply Landscape: Transdermal vs. Other Nitroglycerin Forms

The nitroglycerin supply chain challenges are formulation-specific. As of 2026:

Sublingual tablets (Nitrostat and generics): Have experienced the most significant disruption — particularly Pfizer's Nitrostat, which holds a dominant share of this market. These are used primarily for acute angina relief.

Injectable nitroglycerin: Periodically constrained, impacting hospital formulary management for acute cardiac management.

Transdermal patches (Nitro-Dur, Minitran, generics): Generally available, but patients may encounter localized stock-outs. When sublingual tablets are scarce, some providers transition patients to patches, creating secondary demand pressure.

Translingual sprays (Nitrolingual, Nitromist): Available but at a significantly higher cost than tablets; reasonable alternative for acute use if tablets are unavailable.

Root Causes of Nitroglycerin Supply Constraints

Understanding the underlying drivers helps set realistic expectations for patients and for practice-level planning:

Specialized API manufacturing: Pure nitroglycerin is a regulated explosive. API production requires specialized infrastructure, limiting the number of facilities globally that can supply pharmaceutical manufacturers.

Market consolidation: A small number of companies manufacture the majority of nitroglycerin-based products. Disruptions at any one facility have outsized effects on national supply.

Generic market economics: Low profit margins on generic nitroglycerin products reduce incentive to build excess manufacturing capacity, leaving the supply chain thin when demand fluctuates.

Clinical Management: Therapeutic Alternatives to Nitro-Dur Patches

For patients on Nitro-Dur for chronic angina prophylaxis who encounter persistent patch unavailability, the following alternatives are clinically reasonable and should be individualized based on patient history, comorbidities, and concurrent medications:

Generic nitroglycerin transdermal patch (Minitran, generic NTS): First-line substitution. FDA-rated bioequivalent; specify that pharmacist may substitute any generic at the same mg/hr dose.

Isosorbide mononitrate (Imdur) 30–120 mg extended-release: Once-daily oral long-acting nitrate. Must counsel patients on maintaining the nitrate-free interval (typically an eccentric dosing schedule). Widely available and inexpensive as generic.

Isosorbide dinitrate (Isordil) 10–40 mg TID: Shorter-acting alternative; requires more frequent dosing with asymmetric schedule to maintain nitrate-free interval. Good choice when patient adherence to complex regimens is reliable.

Beta-blocker optimization: For patients not yet on maximally tolerated beta-blocker therapy, this may be the opportunity to optimize metoprolol succinate or bisoprolol dosing before transitioning nitrate formulations.

Calcium channel blockers: Amlodipine or diltiazem as antianginal agents, particularly in patients with concurrent hypertension or vasospastic angina.

Key Prescribing Adjustments to Facilitate Dispensing

Small changes to how prescriptions are written can dramatically reduce patient friction during periods of limited supply:

Write prescriptions as "nitroglycerin transdermal patch [X] mg/hr — brand or generic substitution permitted"

Issue 90-day prescriptions to facilitate mail-order pharmacy utilization and reduce refill frequency

Proactively send in early refill requests or have patients refill at 75% completion rather than waiting until the last few days

Document the medical necessity for specific formulations if prior authorization is required for brand-name dispensing under patient insurance plans

Counseling Patients on the Supply Situation

Proactive patient counseling prevents the dangerous scenario of patients simply going without medication when their pharmacy is out of stock. Recommended patient guidance includes:

Never abruptly discontinue nitroglycerin patches — notify the provider immediately if they can't fill the prescription

Always keep at least a 5–7 day supply buffer to allow time for finding alternate stock sources

Direct patients to tools like medfinder for providers to help them locate in-stock pharmacies near them without placing additional burden on practice staff

Additional Resources

For patient-facing information: Nitro-Dur shortage update for patients | Visit medfinder for providers to learn how medfinder helps your patients find medications in stock.